



Sociedad Argentina de
Terapia Radiante Oncológica

RT CHICAGO / VIENA

7 de Agosto de 2025

Asociación Médica Argentina

Av. Santa Fe 1171 - Buenos Aires

PROGRAMA

08:00 - 08:45 hs. Acreditación y Café de Bienvenida

08:45 - 08:50 hs. Palabras de Bienvenida

**Dr. Jorge Palazzo - Presidente SATRO
VIDT Centro Médico, Tucumán**

08:50 - 09:00 hs. Presentación de la Jornada

Directores:

**Dr. Ariel Gómez Palacios
Centro de Radioterapia Dean Funes, Córdoba**

**Dr. Mauro Mattio
Hospital Bernadino Rivadavia, Buenos Aires**

**Dra. Ofelia Pérez Conci
Centro de Radioterapia Dean Funes, Córdoba**

**Dr. Javier Otero
VIDT Centro Médico, Buenos Aires**

09:00 - 10:00 hs. Módulo 1: Cáncer Gastrointestinal

Presidente: Dr. Ariel Gomez Palacios,
Centro de Radioterapia Dean Funes, Córdoba

Coordinador: Dr. Juan Galarraga,
Centro de Oncología y Radioterapia, Mar del Plata

09:00 - 09:10 hs. Dra. Belén Raiden,
Centro de Radioterapia Dean Funes, Córdoba

- STAR-TREC (NCT02945566): A randomised phase II/III trial of CRT versus 5x5 Gy SCRT for organ preservation in early/intermediate risk rectal cancer
- Organ preservation and quality of life after TNT for locally advanced rectal cancer: a study of the German Rectal Cancer Study Group (CAO/ARO/AIO-16)

09:10 - 09:20 hs. Dr. Pablo Marengo, Hospital de Oncología Marie Curie, BA

- Short-term radiotherapy plus chemotherapy for locally advanced rectal cancer: 5-year outcomes of the phase III clinical trial STELLAR I
- Preoperative Short-course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer: Phase II Results of STELLAR II

09:20 - 09:30 hs. Dra. Mariana Galli, Instituto Alexander Fleming, Bs. As.

- ARISTOTLE: Mature results of a phase 3 trial evaluating the addition of irinotecan to capecitabine chemoradiation in locally advanced rectal cancer
- PRIME-RT: Durvalumab with extended neoadjuvant regimens in locally advanced rectal cancer (LARC): a randomised phase II trial

09:30 - 09:45 hs. Dra. Eugenia Furno, GO Instituto de Tumores, Rosario

- PLATO ACT 4: Long term results of an RCT evaluating reduced dose and standard dose chemoradiotherapy in early-stage anal cancer.
- Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): First results of overall survival (OS) from CheckMate 577.
- A phase III randomized clinical trial evaluating perioperative therapy (neoadjuvant chemotherapy versus chemoradiotherapy) in locally advanced gallbladder cancers (POLCAGB).

9:45 - 10:05 hs. Mesa de Discusión

Coordinador: Dr. Juan Galarraga (RT)

Panelistas: Dr. Ariel Gómez Palacios (RT), Dra. Belén Raiden, (RT),
Dr. Pablo Marengo (RT), Dra. Mariana Galli (RT),
Dra. Eugenia Furno (RT),
Dr. Abrahams Ocanto, Radioncólogo (RT), Genesis Care, España
Dr. Federico Estesó, Oncología Clínica, Inst. Alexander Fleming, BA

10:05 - 10:35 hs. Simposio Sponsor

10:35 - 11:05 hs. Intervalo Café

11:05 - 11:55 hs. Módulo 2: Misceláneas

Presidente: Dr. Marcelo Andrade Irusta, CEMIC, Buenos Aires

Coordinador: Dr. José Máximo Barros, Hospital Universitario Austral, Bs. As.

11:05 - 11:15 hs. Dr. Matías Zapata, VIDT Oncología Radiante, Buenos Aires

- SWOG/NRG S1914: Randomized phase III trial of induction/consolidation atezolizumab + SBRT versus SBRT alone in high risk, early-stage NSCLC.
- Randomized phase II trial investigating whether atezolizumab after chemoradiotherapy (CRT) prolongs survival in limited stage (LS) small cell lung cancer (SCLC). ASCO

11:15 - 11:25 hs. Dra. Pamela Aquino Cardozo, Salud Concordia, Paraguay.

- PD-1 blockade with toripalimab incorporated into induction chemotherapy and radiotherapy with or without concurrent cisplatin in locoregionally advanced nasopharyngeal carcinoma (DIAMOND): A multicenter, non-inferiority, phase 3, randomized controlled trial.
- NIVOPOSTOP (GORTEC 2018-01): A phase III randomized trial of adjuvant nivolumab added to radio-chemotherapy in patients with resected head and neck squamous cell carcinoma at high risk of relapse.

**11:25 - 11:35 hs. Dr. Emilio Astiz,
Instituto Privado de Radioterapia Cuyo, Mendoza**

- Safety of metastasis-directed SBRT in oligometastatic patients treated with and without concomitant systemic therapy: an interim analysis of OligoCare
- Hippocampal-avoidance whole-brain radiotherapy with dose escalation on metastases - Results of a prospective randomized trial (HIPPORAD)

11:35 - 11:55 hs. Mesa de discusión

Coordinador: Dr. José Máximo Barros (RT)

**Panelistas: Dr. Marcelo Andrade Irusta (RT), Dr. Matías Zapata (RT),
Dra. Pamela Aquino Cordozo (RT), Dr. Emilio Astiz (RT)**

11:55 - 12:55 hs. Módulo 3: Cáncer Genitourinario

Presidente: Dr. Javier Otero
VIDT Oncología Radiante, Buenos Aires

Coordinadora: Dra. Carolina Chacón
Instituto Alexander Fleming, Buenos Aires

11:55 - 12:05 hs. Dra. Iara Rivas, VIDT Oncología Radiante, Buenos Aires

- Ultra-hypofractionated radiotherapy for localised prostate cancer: 10-year outcomes of the HYPO-RT-PC phase 3 trial (ISRCTN45905321)
- Focal boost to the intraprostatic tumor for intermediate and high risk prostate cancer: 10-year results of the FLAME-trial

**12:05 - 12:15 hs. Dr. Pablo Andrada,
Hospital Bernardino Rivadavia, Buenos Aires**

- PEACE V - Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM), a randomized phase II trial: report of the primary endpoint
- PERSIAN TRIAL (NCT03449719): Apalutamide and stereotactic body radiation therapy in patients affected by hormone-sensitive prostate cancer

12:15 - 12:25 hs. Dra. Carolina Gatto, Mevaterapia Oncología Radiante, BA

- Stereotactic body radiotherapy vs HDR brachytherapy for prostate cancer: the SHERBET individual patient data meta-analysis of five prospective trials
- Liquid biopsy-based molecular characterization of oligometastatic state in prostate cancer: the RADIOSA trial (NCT03940235) biology task

12:25 - 12:35 hs. Dr. Sergio Quiceno, Hospital Universitario Austral, BA

- Combining SBRT and durvalumab in hormone-sensitive prostate cancer with oligorecurrent metastases: a randomized phase II trial (POSTCARD GETUG P13)
- Nivolumab plus chemoradiotherapy in patients with muscle-invasive bladder: final results of a phase II, randomized study by the HGUCG

12:35 - 12:55 hs. Mesa de Discusión

Coordinadora: Dra. Carolina Chacón (RT)

Panelistas: Dr. Javier Otero (RT), Dra. Iara Rivas (RT), Dr. Pablo Andrada (RT),
Dra. Carolina Gatto (RT), Dr. Sergio Quiceno (RT)
Dra. Carolina Passarella, Oncología Clínica,
Hospital Universitario Austral, Buenos Aires

12:55 - 14:30 hs. Intervalo Almuerzo

14:30 - 15:15 hs. Módulo 4: Cáncer Ginecológico

Presidente: Dr. Mauro Mattio, Hospital Bernardino Rivadavia, Buenos Aires

Coordinador: Dr. Gastón Lemoine, Instituto de Radiaciones, Salta

14:30 - 14:40 hs. Dra. Ana Josefina Llanos, VIDT Oncología Radiante, Bs.As.

- EMBRACE II Trial. Overall Results of on IGRT-IMRT+cisplatin +MR-IGABT in LA Cervix Cancer
- PORTEC-4a: International randomised trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer

14:40 - 14:55 hs. Dr. Lucas Staringer, Mevaterapia Oncología Radiante, BA

- Pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer: Final analysis results of the phase 3, randomized, double-blind ENGOT-cx11/GOG-3047/KEYNOTE-A18 study.
- Induction chemotherapy followed by standard chemoradiotherapy versus standard chemoradiotherapy alone in patients with locally advanced cervical cancer (GCIG INTERLACE): an international, multicentre, randomised phase 3 trial
- Chemoradiation and IGBT Alone or in combination with Protein Kinase inhibitor in Stage III Cervical cancer: Results for Phase III Randomized trial.

14:55 - 15:15 hs. Mesa de discusión

Coordinador: Dr. Gastón Lemoine (RT)

Panelistas: Dr. Mauro Mattio (RT), Dra. Ana Josefina Llanos(RT),
Dr. Lucas Staringer (RT)

Dra. Luciana Brun (RT), Centro de Radioterapia Dean Funes, Córdoba
Dra. Vanesa López, Oncología Clínica, Instituto Ángel Roffo, Bs. As.

15:15 - 15:45 hs. Simposio Sponsor

15:45 - 16:40 hs. Módulo 5: Cáncer de Mama

Presidente: Dra. Ofelia Pérez Conci
Centro de Radioterapia Dean Funes, Córdoba

Coordinadora: Dra. María Fernanda Díaz Vázquez
Centro de Radioterapia Dean Funes, Córdoba

15:45 - 15:55 hs. Dra. Delfina Batisti, VIDT Oncología Radiante, Buenos Aires

- FAST-Forward nodal sub-study: 5-year normal tissue effects following 1-week versus 3-week axillary radiotherapy for breast cancer
- Hypofractionated breast radiotherapy for 1 week vs 3 weeks: 10-year efficacy and late normal tissue effects in the FAST-Forward randomised trial

**15:55 - 16:10 hs. Dra. Ana Faime Raies,
Centro de Radioterapia Dean Funes, Córdoba**

- Early Results of the French Multicenter, Randomized SHARE Trial Comparing Whole Breast Irradiation vs. Accelerated Partial Breast Irradiation in Postmenopausal Women with Early-Stage Breast Cancer
- OPAR: A Randomized Trial of Partial Breast Irradiation in Five Fractions Once Daily for Early Breast Cancer
- DBCG Skagen trial I: Phase III randomised trial of hypo- vs standard fractionated loco-regional radiotherapy in node-positive breast cancer patients

16:10 - 16:20 hs. Dr. Andrés Rodríguez Mignola, CEMIC, Buenos Aires

- Does postmastectomy radiotherapy in 'intermediate-risk' breast cancer impact overall survival? 10 year results of the BIG 2-04 MRC randomized trial on behalf of the SUPREMO trial investigators
- Single-modality endocrine therapy versus radiotherapy after breast-conserving surgery in women aged 70 years and older with luminal A-like early breast cancer (EUROPA): a preplanned interim analysis of a phase 3, non-inferiority, randomised trial

16:20 - 16:40 hs. Mesa de Discusión

Coordinadora: Dra. María Fernanda Díaz Vázquez (RT)

Panelistas: Dra. Ofelia Pérez Conci (RT), Dra. Delfina Batisti (RT),
Dra. Ana F. Raies (RT), Dr. Andrés Rodríguez Mignola (RT),
Dra. Vanesa Krakowsky (RT), VIDT Oncología Radiante, BA
Dra. Leticia Alvarado (RT), Hope International, Guatemala
Dra. María Eugenia Azar, Mastología, Inst. Oncológico Ángel Roffo, BA
Dra. Liliana Zamora, Ginecología Oncológica, Hospital Italiano, BA

16:40 - 16:45 hs. Cierre de la Jornada